{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T05:45:17Z","timestamp":1768974317198,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We compared transplantation outcomes of AML patients with\n                    <jats:italic>WT1<\/jats:italic>\n                    mutation (mWT1), identified by next-generation sequencing, to those of patients with wild-type\n                    <jats:italic>WT1<\/jats:italic>\n                    AML (wtWT1). 703 patients were included, 50 with mWT1 and 653 with wtWT1. Patients with mWT1 were younger (median age: 45.6 vs. 56.4 years,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), with a higher proportion of females (66% vs. 47.6%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.01), higher frequency of mutations in\n                    <jats:italic>FLT3-ITD<\/jats:italic>\n                    (38.3% vs. 21.7%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.01) and\n                    <jats:italic>CEBPA<\/jats:italic>\n                    (15.8% vs. 5.7%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.03). Donors were matched siblings in 30.6%, unrelated in 45.6%, and haploidentical in 22.1%. A higher percentage of mWT1 vs. wtWT1 patients received in vivo T-cell depletion (66% vs. 51%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.03) and 58% vs. 47.1% received myeloablative conditioning. 49 patients with mWT1 were matched to 127 wtWT1 patients in matched-pairs analysis. Outcomes (mWT1 vs. wtWT1) were not significantly different: relapse (2\u2009y: 28.8% vs. 30.4%, HR: 1.14,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.64), NRM (2\u2009y: 15.5% vs. 9.9%, HR: 1.41,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.49), LFS (2\u2009y: 55.7% vs. 59.6%, HR: 1.21,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.39), OS (2\u2009y: 65.4% vs. 73.3%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.66), and chronic GVHD (2\u2009y:24.3% vs. 25.4%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.95). In conclusion,\n                    <jats:italic>WT1<\/jats:italic>\n                    mutation did not influence transplantation outcomes of AML patients in CR1.\n                  <\/jats:p>","DOI":"10.1038\/s41409-025-02727-7","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T15:19:41Z","timestamp":1760627981000},"page":"44-50","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of Wilms\u2019 tumor 1 gene (WT1) mutation on outcome of allogeneic hematopoietic-cell transplantation for acute myeloid leukemia: a retrospective multicenter cohort study from the ALWP\/EBMT registry"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0763-1265","authenticated-orcid":false,"given":"Arnon","family":"Nagler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8056-648X","authenticated-orcid":false,"given":"Jordi","family":"Esteve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9102-4427","authenticated-orcid":false,"given":"Jacques-Emmanuel","family":"Galimard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6934-4619","authenticated-orcid":false,"given":"Jaime","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1897-0227","authenticated-orcid":false,"given":"Xavier","family":"Poire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Collin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4257-5980","authenticated-orcid":false,"given":"Johan","family":"Maertens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maija","family":"It\u00e4la-Remes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1161-9138","authenticated-orcid":false,"given":"Khalid","family":"Halahleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jes\u00fas","family":"Pascual Cascon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1355-1587","authenticated-orcid":false,"given":"Patrizia","family":"Chiusolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laimonas","family":"Griskevicius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3170-1016","authenticated-orcid":false,"given":"Ain","family":"Kaare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0947-8708","authenticated-orcid":false,"given":"Ann","family":"De Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8415-7069","authenticated-orcid":false,"given":"Pavel","family":"Jindra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3616-6101","authenticated-orcid":false,"given":"Jose Antonio","family":"P\u00e9rez-Sim\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7171-4997","authenticated-orcid":false,"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4471-418X","authenticated-orcid":false,"given":"Eolia","family":"Brissot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0873-0123","authenticated-orcid":false,"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"2727_CR1","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood"},{"key":"2727_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, Wei AH, Appelbaum FR, Craddock C, Dinardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel on behalf of ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"2727_CR3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1182\/bloodadvances.2016000760","volume":"1","author":"L Quek","year":"2016","unstructured":"Quek L, Ferguson P, Metzner M, Ahmed I, Kennedy A, Garnett C, et al. Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia. Blood Adv. 2016;1:193\u2013204.","journal-title":"Blood Adv"},{"key":"2727_CR4","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/j.bbmt.2016.07.018","volume":"22","author":"MR Luskin","year":"2016","unstructured":"Luskin MR, Carroll M, Lieberman D, Morrissette JD, Zhao J, Crisalli L, et al. Clinical utility of next-generation sequencing for oncogenic mutations in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transpl. 2016;22:1961\u20137.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2727_CR5","doi-asserted-by":"publisher","first-page":"5201","DOI":"10.3390\/curroncol30060395","volume":"30","author":"F Guijarro","year":"2023","unstructured":"Guijarro F, Garrote M, Villamor N, Colomer D, Esteve J, L\u00f3pez-Guerra M. Novel tools for diagnosis and monitoring of AML. Curr Oncol. 2023;30:5201\u201313.","journal-title":"Curr Oncol"},{"key":"2727_CR6","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1182\/blood.2024025409","volume":"144","author":"H D\u00f6hner","year":"2024","unstructured":"D\u00f6hner H, DiNardo CD, Appelbaum FR, Craddock C, Dombret H, Ebert BL, et al. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024;144:2169\u201373.","journal-title":"Blood"},{"key":"2727_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32103-8","volume":"13","author":"Y Tazi","year":"2022","unstructured":"Tazi Y, Arango-Ossa JE, Zhou Y, Bernard E, Thomas I, Gilkes A, et al. Unified classification and risk-stratification in acute myeloid leukemia. Nat Commun. 2022;13:4622.","journal-title":"Nat Commun"},{"key":"2727_CR8","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/s41375-023-01884-2","volume":"37","author":"C Rausch","year":"2023","unstructured":"Rausch C, Rothenberg-Thurley M, Dufour A, Schneider S, Gittinger H, Sauerland C, et al. Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia. 2023;37:1234\u201344.","journal-title":"Leukemia"},{"key":"2727_CR9","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/s41375-023-01846-8","volume":"37","author":"K Mr\u00f3zek","year":"2023","unstructured":"Mr\u00f3zek K, Kohlschmidt J, Blachly JS, Nicolet D, Caroll AJ, Archer K, et al. Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an alliance study. Leukemia. 2023;37:788\u201398.","journal-title":"Leukemia"},{"key":"2727_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/16078454.2020.1720102","volume":"25","author":"J Xu","year":"2020","unstructured":"Xu J, Zhang Y, Hu J, Ren Y, Wang H. Clinical features and prognosis of normal karyotype acute myeloid leukemia pediatric patients with WT1 mutations: an analysis based on TCGA database. Hematology. 2020;25:79\u201384.","journal-title":"Hematology"},{"key":"2727_CR11","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2023.2285801","volume":"24","author":"T Yu","year":"2023","unstructured":"Yu T, Zhan Q, Yan X, Luo X, Wang X, Tang X, et al. Clinical significance of WT1 in the evaluation of therapeutic effect and prognosis of non-M3 acute myeloid leukemia. Cancer Biol Ther. 2023;24:2285801.","journal-title":"Cancer Biol Ther"},{"key":"2727_CR12","first-page":"179","volume":"10","author":"I Haider","year":"2020","unstructured":"Haider I, Kumar C, Jain G, Bakhshi S, Kumar L, Chopra A, et al. Hotspots mutational analysis of Wilms tumor 1 gene in acute myeloid leukemia: prevalence and clinical correlation in North Indian population. Am J Blood Res. 2020;10:179\u201389.","journal-title":"Am J Blood Res"},{"key":"2727_CR13","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3324\/haematol.2021.279601","volume":"107","author":"MJ Christopher","year":"2022","unstructured":"Christopher MJ, Katerndahl CDS, LeBlanc HR, Elmendorf TT, Basu V, Gang M, et al. Tumor suppressor function of WT1 in acute promyelocytic leukemia. Haematologica. 2022;107:342\u20136.","journal-title":"Haematologica"},{"key":"2727_CR14","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1002\/cncr.24442","volume":"16","author":"A Renneville","year":"2009","unstructured":"Renneville A, Boissel N, Zurawski V, Llopis L, Biggio V, Nibourel O, et al. Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association. Cancer. 2009;16:3719\u201327.","journal-title":"Cancer"},{"key":"2727_CR15","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.1200\/JCO.2009.22.4865","volume":"27","author":"D Cilloni","year":"2009","unstructured":"Cilloni D, Renneville A, Hermitte F, Hills RK, Daly S, Jovanovic JV, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol. 2009;27:5195\u2013201.","journal-title":"J Clin Oncol"},{"key":"2727_CR16","doi-asserted-by":"publisher","first-page":"5222","DOI":"10.1182\/blood-2009-12-259390","volume":"115","author":"HA Hou","year":"2010","unstructured":"Hou HA, Huang TC, Lin LI, Liu CY, Chen CY, Chou WC, et al. WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. Blood. 2010;115:5222\u201331.","journal-title":"Blood"},{"key":"2727_CR17","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/cts.12669","volume":"6","author":"DR Buelow","year":"2019","unstructured":"Buelow DR, Pounds SB, Wang YD, Shi L, Li Y, Finkelstein D, et al. Uncovering the genomic landscape in newly diagnosed and relapsed pediatric cytogenetically normal FLT3-ITD AML. Clin Transl Sci. 2019;6:641\u2013647.","journal-title":"Clin Transl Sci"},{"key":"2727_CR18","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1182\/blood-2010-02-268953","volume":"116","author":"PA Ho","year":"2010","unstructured":"Ho PA, Zeng R, Alonzo TA, Gerbing RB, Miller KL, Pollard JA, et al. Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children\u2019s Oncology Group. Blood. 2010;116:702\u201310.","journal-title":"Blood"},{"key":"2727_CR19","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.1182\/blood-2022-166323","volume":"140","author":"X Pan","year":"2022","unstructured":"Pan X, Mengge G, Wang K, Wang Y, Kong J, Sun Y, et al. Prognostic impact of WT1 mutation on AML of different risk groups based on 2022 European Leukemianet (ELN) risk classification. Blood. 2022;140:3216\u20137.","journal-title":"Blood"},{"key":"2727_CR20","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1182\/bloodadvances.2023010960","volume":"8","author":"A Baranwal","year":"2024","unstructured":"Baranwal A, Basmaci R, He R, Viswanatha D, Greipp P, Murthy HS, et al. Genetic features and outcomes of allogeneic transplantation in patients with WT1-mutated myeloid neoplasms. Blood Adv. 2024;8:562\u201370.","journal-title":"Blood Adv"},{"key":"2727_CR21","doi-asserted-by":"publisher","first-page":"e581","DOI":"10.3324\/haematol.2018.193102","volume":"103","author":"S Vosberg","year":"2018","unstructured":"Vosberg S, Hartmann L, Metzeler KH, Konstandin NP, Schneider S, Bohlander SK, et al. Relapse of acute myeloid leukemia after allogeneic stem cell transplantation is associated with gain of WT1 alterations and high mutation load. Haematologica. 2018;103:e581\u201384.","journal-title":"Haematologica"},{"key":"2727_CR22","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/s41409-021-01538-w","volume":"57","author":"S El Hussein","year":"2022","unstructured":"El Hussein S, DiNardo CD, Takahashi K, Khoury JD, Fang H, Furudate K, et al. Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant. Bone Marrow Transpl. 2022;57:370\u20136.","journal-title":"Bone Marrow Transpl"},{"key":"2727_CR23","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1182\/blood-2023-188319","volume":"142","author":"H Atluri","year":"2023","unstructured":"Atluri H, DiGennaro J, Patel KP, Routbort M, Oran B, Isaa GC, et al. Clinical and prognostic implications of WT1 mutations in De Novo and relapsed acute myeloid leukemia. Blood. 2023;142:959.","journal-title":"Blood"},{"key":"2727_CR24","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009;15:1628\u20133320.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2727_CR25","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. Consensus conference on acute GVHD grading. Bone Marrow Transpl. 1995;15:825\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"2727_CR26","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","volume":"69","author":"HM Shulman","year":"1980","unstructured":"Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204\u201317.","journal-title":"Am J Med"},{"key":"2727_CR27","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1002\/sim.5753","volume":"32","author":"DF McCaffrey","year":"2013","unstructured":"McCaffrey DF, Griffin BA, Almirall D, Slaughter ME, Ramchand R, Burgette LF. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat Med. 2013;32:3388\u2013414.","journal-title":"Stat Med"},{"key":"2727_CR28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2991\/chi.d.191207.001","volume":"2","author":"AS Kanate","year":"2019","unstructured":"Kanate AS, Nagler A, Savani B. Summary of scientific and statistical methods, study endpoints and definitions for observational and registry-based studies in hematopoietic cell transplantation. Clin Hematol Int. 2019;2:2\u20134.","journal-title":"Clin Hematol Int"},{"key":"2727_CR29","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1002\/(SICI)1097-0258(19990630)18:12<1489::AID-SIM140>3.0.CO;2-#","volume":"18","author":"PK Andersen","year":"1999","unstructured":"Andersen PK, Klein JP, Zhang MJ. Testing for center effects in multi-center survival studies: a Monte Carlo comparison of fixed and random effects tests. Stat Med. 1999;18:1489\u2013500.","journal-title":"Stat Med"},{"key":"2727_CR30","unstructured":"R Core Team. R: A language and environment for statistical computing. Vienna, R Foundation for Statistical Computing; 2020. https:\/\/www.R-project.org\/"},{"key":"2727_CR31","doi-asserted-by":"publisher","first-page":"5429","DOI":"10.1200\/JCO.2008.16.0333","volume":"26","author":"P Virappane","year":"2008","unstructured":"Virappane P, Gale R, R Hills R, Kakkas I, Summers K, Stevens J, et al. Mutation of the Wilms\u2019 tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2008;26:5429\u201335.","journal-title":"J Clin Oncol"},{"key":"2727_CR32","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.1200\/JCO.2007.15.2058","volume":"26","author":"P Paschka","year":"2008","unstructured":"Paschka P, Marcucci G, Ruppert AS, Whitman SP, Mr\u00f3zek K, Maharry K, et al. Wilms\u2019 tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: Cancer and Leukemia Group B study. J Clin Oncol. 2008;26:4595\u2013460230.","journal-title":"J Clin Oncol"},{"key":"2727_CR33","first-page":"22","volume":"40","author":"S Ma","year":"2025","unstructured":"Ma S, Tang L, Tang H, Wu C, Pu X, Yang J, et al. WT1 and DNMT3A mutations in prognostic significance of acute myeloid leukemia: a meta-analysis. Cancer Biother Radiopharm. 2025;40:22\u201330.","journal-title":"Cancer Biother Radiopharm"},{"key":"2727_CR34","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.1182\/blood-2008-10-183392","volume":"113","author":"VI Gaidzik","year":"2009","unstructured":"Gaidzik VI, Schlenk RF, Moschny S, Becker A, Bullinger L, Corbacioglu A, et al. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML study group. Blood. 2009;113:4505\u201311.","journal-title":"Blood"},{"key":"2727_CR35","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1111\/bjh.19721","volume":"205","author":"N Xu","year":"2024","unstructured":"Xu N, Dao FT, Shi ZY, Sun K, Qin YZ. WT1 together with RUNX1:RUNX1T1 targets DUSP6 to dampen ERK activity in acute myeloid leukaemia. Br J Haematol. 2024;205:1848\u201359.","journal-title":"Br J Haematol"},{"key":"2727_CR36","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1007\/s00277-024-05870-1","volume":"103","author":"W Guo","year":"2024","unstructured":"Guo W, Zhang H, Wang M, Zheng Y, Cao Y, Zhang X, et al. WT1 gene mutations impact post-transplant relapse in myelodysplastic syndrome with excess blasts 2 patients. Ann Hematol. 2024;103:2827\u201336.","journal-title":"Ann Hematol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02727-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02727-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02727-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T16:39:11Z","timestamp":1768927151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02727-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2727"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02727-7","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"assertion":[{"value":"7 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The scientific boards of the ALWP of the EBMT approved this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}